// App-Quantinova.ai

263 : Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period

Researchers

Presenter

  • Iain B McInnes

Principal Investigators

  • Atul Deodhar

  • Dafna D Gladman

  • Mengyuan Ren

  • Sebastian Spindeldreher

  • Luminita Pricop

  • Brian Porter

  • Jorge Safi

  • Abhijit Shete

  • Gerard Bruin

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Institute of Medical Science, Toronto Western Hospital, Toronto, ON, CANADA

  • Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA

  • Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, SWITZERLAND

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

  • Novartis Pharmaceuticals Corporation, Novartis Pharma AG, East Hanover, NJ

Locations

  • United Kingdom

  • United States

  • Canada

  • China

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

  • Psoriatic arthritis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

  • Interleukin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved